Business
Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
GLEN ALLEN, Va., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that Cary Claiborne, CEO of Adial, will be presenting at the Oppenheimer 36th Annual Healthcare Life Sciences Conference which will be held virtually February 25 - 26, 2026. Adial’s presentation is scheduled for Wednes
About this update from Adial Pharmaceuticals, Inc
[{"type":"image","alt":"Adial Pharmaceuticals, Inc","displaySize":"","headline":null,"caption":"Adial Pharmaceuticals, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":282,"height":123,"url":"https://media.zenfs.com/en/globenewswire.com/1a7a0a453f63a638e99b1c536ceba3a8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fKhTAZbrVcry7QkXYXjJNA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1a7a0a453f63a638e99b1c536ceba3a8","width":282,"height":123}},"lazy":false},{"type":"text","content":"GLEN ALLEN, Va., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that Cary Claiborne, CEO of Adial, will be presenting at the Oppenheimer 36th Annual Healthcare Life Sciences Conference which will be held virtually February 25 - 26, 2026.","length":455,"tagName":"p"},{"type":"text","content":"Adial’s presentation is scheduled for Wednesday, February 25, 2026 at 2:40 p.m. Eastern Time. The presentation will be webcast live and available for replay at https://event.summitcast.com/view/CTtthLh2Bi2D9aYoKpvtEv/UHEtM9jk8GYPk2uPyMKHVc as well as on the Company's investor relations section of the website at www.adial.com/events.","length":348,"tagName":"p"},{"type":"text","content":"Management will also be hosting 1x1 meetings throughout the conference with approved investors.","length":95,"tagName":"p"},{"type":"text","content":"About Adial Pharmaceuticals, Inc. Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s companion diagnostic genetic test. ONWARD showed promising results in reducing drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also...